Compare STWD & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STWD | CRL |
|---|---|---|
| Founded | 2009 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.0B |
| IPO Year | 2009 | 2000 |
| Metric | STWD | CRL |
|---|---|---|
| Price | $18.20 | $180.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $20.63 | ★ $205.27 |
| AVG Volume (30 Days) | ★ 3.6M | 699.0K |
| Earning Date | 02-25-2026 | 02-18-2026 |
| Dividend Yield | ★ 10.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | $490,651,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | $366.38 | N/A |
| Revenue Next Year | $12.15 | $1.70 |
| P/E Ratio | $17.27 | ★ N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $16.59 | $91.86 |
| 52 Week High | $21.05 | $228.88 |
| Indicator | STWD | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 30.69 |
| Support Level | $17.88 | $181.77 |
| Resistance Level | $18.49 | $218.69 |
| Average True Range (ATR) | 0.29 | 7.82 |
| MACD | -0.00 | -4.97 |
| Stochastic Oscillator | 60.11 | 5.28 |
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment, and Investing & Servicing Segment. The company generates the majority of its revenue from the Commercial and Residential Lending Segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.